Literature DB >> 8329798

Nicotine transdermal systems.

M L Gora1.   

Abstract

OBJECTIVE: To review the role of transdermal nicotine as an aid to smoking cessation. DATA SOURCES: A MEDLINE search was performed that included clinical studies published in English involving transdermal nicotine; references used in those articles were screened for additional published information. STUDY SELECTION: Published clinical trials were reviewed with particular emphasis on controlled trials that evaluated safety and efficacy. DATA SYNTHESIS: Transdermal nicotine therapy has been shown to be a safe and effective pharmacologic aid in a smoking cessation program when used in conjunction with a psychologic or behavior support system. Habitrol, Nicoderm, Nicotrol, and PROSTEP differ in some characteristics (i.e., delivery systems, total nicotine content and amount absorbed, rate of delivery, recommended duration of application); however, the clinical implication of these differences has not been determined.
CONCLUSIONS: Transdermal nicotine is effective for patients who are motivated to quit smoking and receive concomitant behavior support.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8329798     DOI: 10.1177/106002809302700615

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  3 in total

Review 1.  Optimisation of treatment by applying programmable rate-controlled drug delivery technology.

Authors:  Yie W Chien; Senshang Lin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Nicotine addiction. How can we help?

Authors:  S A Taylor
Journal:  Can Fam Physician       Date:  1994-09       Impact factor: 3.275

3.  Effects of transdermal nicotine on lower esophageal sphincter and esophageal motility.

Authors:  S C Kadakia; H R De La Baume; R T Shaffer
Journal:  Dig Dis Sci       Date:  1996-11       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.